Skip to main content
Premium Trial:

Request an Annual Quote

Silence Therapeutics Issued Notice of Allowance for US Patent Application on Cancer Target

Premium

Silence Therapeutics said this week that it has received a notice of allowance from the US Patent and Trademark Office on a patent application directed to a cancer target and the use of RNAi molecules against it.

The target, PKN-3, is a protein kinase C-related molecule associated with the growth of cancer cells, as well as metastasis formation, and is the target for the company's phase I siRNA-based solid tumor drug Atu-027.

"The allowed subject matter is directed to, among other things, methods of treating cancer with small interfering RNA or antisense molecules that target the PKN-3 messenger RNA," the company said.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.